CN109715165A - 巨环激酶抑制剂 - Google Patents

巨环激酶抑制剂 Download PDF

Info

Publication number
CN109715165A
CN109715165A CN201780056515.5A CN201780056515A CN109715165A CN 109715165 A CN109715165 A CN 109715165A CN 201780056515 A CN201780056515 A CN 201780056515A CN 109715165 A CN109715165 A CN 109715165A
Authority
CN
China
Prior art keywords
alkyl
yuan
nhc
nhs
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056515.5A
Other languages
English (en)
Chinese (zh)
Inventor
景荣·J·崔
李一山
埃文·W·罗杰斯
翟大勇
J·翁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tp Biopharmaceutical Co
Original Assignee
Tp Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Biopharmaceutical Co filed Critical Tp Biopharmaceutical Co
Publication of CN109715165A publication Critical patent/CN109715165A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CN201780056515.5A 2016-07-28 2017-07-27 巨环激酶抑制剂 Pending CN109715165A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367886P 2016-07-28 2016-07-28
US62/367,886 2016-07-28
PCT/US2017/044214 WO2018022911A1 (en) 2016-07-28 2017-07-27 Macrocycle kinase inhibitors

Publications (1)

Publication Number Publication Date
CN109715165A true CN109715165A (zh) 2019-05-03

Family

ID=61016718

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056515.5A Pending CN109715165A (zh) 2016-07-28 2017-07-27 巨环激酶抑制剂

Country Status (15)

Country Link
US (1) US10689400B2 (https=)
EP (1) EP3490564A4 (https=)
JP (1) JP2019527230A (https=)
KR (1) KR20190034225A (https=)
CN (1) CN109715165A (https=)
AU (1) AU2017302019A1 (https=)
BR (1) BR112019001607A2 (https=)
CA (1) CA3031100A1 (https=)
IL (1) IL264395A (https=)
MX (1) MX2019001125A (https=)
RU (1) RU2019105587A (https=)
SG (1) SG11201900163PA (https=)
TW (1) TW201815799A (https=)
WO (1) WO2018022911A1 (https=)
ZA (1) ZA201901034B (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109516999A (zh) * 2017-11-01 2019-03-26 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
WO2020233645A1 (zh) * 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CN112110938A (zh) * 2019-06-21 2020-12-22 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
CN113354548A (zh) * 2021-04-12 2021-09-07 常熟耐素生物材料科技有限公司 一种基于六亚甲基四胺的植物多烯酚醛胺环氧固化剂及其制备方法
CN113754682A (zh) * 2020-06-04 2021-12-07 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN116063326A (zh) * 2021-11-02 2023-05-05 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
US12129258B2 (en) 2018-04-25 2024-10-29 Primegene (Beijing) Co., Ltd Diaryl macrocyclic compound and pharmaceutical composition, and use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
WO2019184955A1 (en) 2018-03-28 2019-10-03 Fochon Pharmaceuticals, Ltd. Macrocyclic compounds as trk kinases inhibitors
CN117285467A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
CA3134814A1 (en) * 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
EP4114530A4 (en) * 2020-03-02 2024-04-17 Turning Point Therapeutics, Inc. THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
WO2025010294A2 (en) * 2023-07-03 2025-01-09 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as tyk2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
US9833084B2 (en) * 2010-07-01 2017-12-05 The Coca-Cola Company Merchandiser

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195935T1 (de) 1993-03-25 2000-09-15 Upjohn Co Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
KR20110073500A (ko) 2008-09-08 2011-06-29 메르크 파텐트 게엠베하 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
PL2710018T3 (pl) * 2011-05-19 2022-04-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Związki makrocykliczne jako inhibitory kinaz białkowych
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003802A2 (pt) 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
HUE029728T2 (en) * 2011-09-30 2017-03-28 Ipsen Pharma Sas Macrocyclic LRRK2 kinase inhibitors
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
EA201591773A1 (ru) * 2013-03-15 2016-01-29 Онкодизайн С.А. Макроциклические ингибиторы rip2-киназы
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
AU2016287568B2 (en) * 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833084B2 (en) * 2010-07-01 2017-12-05 The Coca-Cola Company Merchandiser
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
CN109516999A (zh) * 2017-11-01 2019-03-26 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
US12129258B2 (en) 2018-04-25 2024-10-29 Primegene (Beijing) Co., Ltd Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
WO2020233645A1 (zh) * 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
CN112110938A (zh) * 2019-06-21 2020-12-22 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
CN113754682A (zh) * 2020-06-04 2021-12-07 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
CN113754682B (zh) * 2020-06-04 2023-01-06 赛诺哈勃药业（成都）有限公司 具有大环结构的化合物及其用途
CN116829562A (zh) * 2021-02-10 2023-09-29 深圳国顺康医药科技有限公司 一种巨环化合物、药物组合物以及其用途
WO2022171139A1 (zh) * 2021-02-10 2022-08-18 北京国鸿生物医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN116829562B (zh) * 2021-02-10 2025-04-01 深圳国顺康医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN113354548A (zh) * 2021-04-12 2021-09-07 常熟耐素生物材料科技有限公司 一种基于六亚甲基四胺的植物多烯酚醛胺环氧固化剂及其制备方法
CN116063326A (zh) * 2021-11-02 2023-05-05 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
WO2023078267A1 (zh) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物

Also Published As

Publication number Publication date
BR112019001607A2 (pt) 2019-04-30
EP3490564A4 (en) 2020-02-26
US20190169208A1 (en) 2019-06-06
IL264395A (en) 2019-02-28
ZA201901034B (en) 2021-06-30
RU2019105587A (ru) 2020-08-28
TW201815799A (zh) 2018-05-01
JP2019527230A (ja) 2019-09-26
US10689400B2 (en) 2020-06-23
CA3031100A1 (en) 2018-02-01
KR20190034225A (ko) 2019-04-01
MX2019001125A (es) 2019-06-12
AU2017302019A1 (en) 2019-02-07
RU2019105587A3 (https=) 2020-11-18
SG11201900163PA (en) 2019-02-27
WO2018022911A1 (en) 2018-02-01
EP3490564A1 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
CN109715165A (zh) 巨环激酶抑制剂
CN114656482B (zh) 作为egfr抑制剂的大环杂环类化合物及其应用
TWI751163B (zh) Ｆｇｆｒ４抑制劑、其製備方法和應用
KR102599788B1 (ko) 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클
WO2021190467A1 (zh) 含螺环的喹唑啉化合物
WO2023280136A1 (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
KR20240040742A (ko) Kif18a 억제제로서의 화합물
WO2021129820A1 (zh) 含螺环的喹唑啉化合物
WO2020239077A1 (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN113527335A (zh) 作为egfr抑制剂的大环类化合物及其应用
CN109745321B (zh) 包含fgfr4抑制剂的药物组合物
EP2168964B1 (en) Azaindole-indole coupled derivatives, preparation methods and uses thereof
US10085983B2 (en) Azabicyclo derivatives, process for preparation thereof and medical use thereof
US20230295163A1 (en) Tetracyclic derivative, method for preparing same and use thereof in medicine
KR20160137576A (ko) ＲＯＳ1 저해제로서의 치환된 4,5,6,7-테트라히드로피라졸로[1,5-ａ]피라진 유도체 및 5,6,7,8-테트라히드로-4Ｈ-피라졸로[1,5-ａ][1,4]디아제핀 유도체
WO2020224626A9 (zh) 用作激酶抑制剂的化合物及其应用
CN114644627A (zh) AhR抑制剂及其用途
CN113518779B (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
EP3805212A1 (en) 3-oxazolinone compound, preparation method therefor and pharmaceutical application thereof
CN116390728A (zh) 喹唑啉衍生物及其制备方法和用途
CN117624179A (zh) 3-(氨基)亚甲基吲哚啉类衍生物及其制备方法和应用
CN117624014A (zh) 3-(吲哚氨基)亚甲基吲哚啉类衍生物及其制备方法和应用
CN115433207A (zh) 作为egfr抑制剂的大环杂环类化合物及其应用
WO2022237825A1 (zh) 具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用
WO2021244505A1 (zh) 新型吡嗪化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: California, USA

Applicant after: Tep Pharmaceutical Company

Address before: California, USA

Applicant before: TP biopharmaceutical company

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190503

WD01 Invention patent application deemed withdrawn after publication